Merck, a leading science and technology company, today announced recipients of the fifth annual Grant for Multiple Sclerosis Innovation (GMSI) during the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. This year, 77 proposals from 25 countries were submitted, representing innovative research projects taking place across the globe.

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) meeting (October 25-28, 2017 Paris, France).

The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of BIOCAD. These are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis.

Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the Group sales rose 5% to CHF 39.4 billion. Sales in the Pharmaceuticals Division increased 5% to CHF 30.6 billion. The recently launched medicines Ocrevus, Tecentriq and Alecensa contributed CHF 0.9 billion to new sales, accounting for more than half of the division's growth.

The Union for International Cancer Control (UICC) and Pfizer Oncology have announced the names of the organisations taking part in the second phase of the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC MBC Challenge). The 20 organisations from 19 countries that have been selected will receive grants amounting to US$500,000 in funding provided by Pfizer to

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment.

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers.